| Literature DB >> 35534765 |
Siming Li1, Xiaoling Li1, Jing Fan2, Xinhang Jia1, Hemeng Wang3,4, Fangxin Dong1, Haoyang Mao1, Chen Zhang1, Wenfei Wang3, Ye Jiang3, Lijun Yan5, Na Zhang6.
Abstract
The aim of this study was to investigate the therapeutic effect of JQ-R on metabolic hypertension and its correlation with Fibroblast growth factor 21/Fibroblast growth factor receptors 1(FGF21/FGFR1) pathway. In this study, fructose-induced metabolic hypertension rats were used as hypertension models to detect the regulation effect of JQ-R on hypertension. The effects of JQ-R on blood glucose, blood lipids, serum insulin levels and other metabolic indicators of rats were also measured. The effects of JQ-R on FGF21/FGFR1 signaling pathway in model animals were detected by Real-time quantitative PCR and Western blotting. The results showed that JQ-R significantly reduce the blood pressure of model rats in a dose-dependent manner. Meanwhile, fasting insulin, fasting blood glucose, insulin resistance index, total cholesterol and triglyceride levels were significantly decreased, and glucose and lipid metabolism abnormalities were also significantly improved. JQ-R induces these changes along with FGFR1 phosphorylation, which was also detected in JQ-R treated FGF21 knockout mice. These results suggest that JQ-R can reduce blood pressure and improve glucose and lipid metabolism in fructose-induced hypertension rats. Activation of FGF21/FGFR1 signaling pathway to regulate downstream blood pressure and glucolipid metabolism-related pathways may be one of the important mechanisms of JQ-R in regulating blood pressure.Entities:
Keywords: ACE2; Akt; FGF21/FGFR1 axis; Metabolic hypertension; Refined-JinQi-JiangTang tablets (JQ-R)
Mesh:
Substances:
Year: 2022 PMID: 35534765 DOI: 10.1007/s11418-022-01626-1
Source DB: PubMed Journal: J Nat Med ISSN: 1340-3443 Impact factor: 3.192